A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.

MR Patel; Matthew J Ahearne; K Linton; C Fox; DJ Lewis; M Higgins; BE Schwartz; PA Beer; MT Tees

doi:10.1200/JCO.2023.41.16_suppl.TPS7591

A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.

MR Patel, Matthew J Ahearne, K Linton, C Fox, DJ Lewis, M Higgins, BE Schwartz, PA Beer, MT Tees

Division of Cancer Sciences (L5)

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Number of pages	1
Journal	Journal of Clinical Oncology
Volume	41
Issue number	16
Early online date	31 May 2023
DOIs	https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS7591
Publication status	Published - 1 Jun 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2023.41.16_suppl.TPS7591

Cite this

@article{36c2435bcc544f1aa519323b92992e76,

title = "A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.",

author = "MR Patel and Ahearne, {Matthew J} and K Linton and C Fox and DJ Lewis and M Higgins and BE Schwartz and PA Beer and MT Tees",

year = "2023",

month = jun,

day = "1",

doi = "10.1200/JCO.2023.41.16_suppl.TPS7591",

language = "English",

volume = "41",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "16",

}

TY - JOUR

T1 - A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.

AU - Patel, MR

AU - Ahearne, Matthew J

AU - Linton, K

AU - Fox, C

AU - Lewis, DJ

AU - Higgins, M

AU - Schwartz, BE

AU - Beer, PA

AU - Tees, MT

PY - 2023/6/1

Y1 - 2023/6/1

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=pure_starter&SrcAuth=WosAPI&KeyUT=WOS:001053772005456&DestLinkType=FullRecord&DestApp=WOS

U2 - 10.1200/JCO.2023.41.16_suppl.TPS7591

DO - 10.1200/JCO.2023.41.16_suppl.TPS7591

M3 - Meeting Abstract

SN - 0732-183X

VL - 41

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 16

ER -

A phase 1/2 study of STP938, a first-in-class inhibitor of CTP synthase 1, in patients with relapsed/refractory B or T cell lymphoma.

UN SDGs

Access to Document

Other files and links

Cite this